Core Viewpoint - The recent election results for the Chinese Academy of Sciences and the Chinese Academy of Engineering highlight a significant focus on cancer research, particularly in liver and gastrointestinal cancers, with notable advancements in prevention and early diagnosis [3][4]. Group 1: New Academicians - A total of 73 new academicians were elected to the Chinese Academy of Sciences, and 71 to the Chinese Academy of Engineering [3]. - Among the newly elected academicians, significant contributions come from experts in clinical medicine, particularly in cancer research [3]. Group 2: Focus on Liver Cancer - The field of liver cancer remains a critical area of research, with approximately 900,000 new cases globally each year, and China accounting for nearly half of these cases [3]. - A major report published in The Lancet by academicians Zhou Jian and Fan Jia indicates that at least 60% of liver cancer cases are preventable through risk factor reduction [4]. Group 3: Innovations in Diagnosis and Treatment - Zhou Jian and Fan Jia have developed a miRNA-based early diagnosis model for liver cancer, which has been successfully transformed into a clinical application, significantly improving early detection rates compared to traditional markers [5]. - The overall survival rate for treated patients has reached an international leading level due to innovative personalized treatment strategies [5]. Group 4: Gastrointestinal Cancer Research - Gastrointestinal cancer also has a high incidence rate in China, with significant contributions from academician Fang Jingyuan in early diagnosis, prevention, and comprehensive treatment strategies [5].

Core Insights - The newly elected academicians from the Chinese Academy of Sciences and the Chinese Academy of Engineering highlight a concentration in the field of oncology and major diseases, with a total of 73 and 71 academicians elected respectively [1][3]. Group 1: Elected Academicians - Among the newly elected academicians, notable experts in clinical medicine include Zhou Jian from Zhongshan Hospital affiliated with Fudan University and Fang Jingyuan from Renji Hospital affiliated with Shanghai Jiao Tong University [1]. - Other elected academicians in clinical medicine include Cai Xiujun from Shao Yifu Hospital affiliated with Zhejiang University and Wang Yongjun from Beijing Tiantan Hospital affiliated with Capital Medical University [1]. Group 2: Focus on Liver Cancer - Zhou Jian specializes in clinical and basic research on liver cancer and has received the National Science and Technology Progress Award five times; he emphasizes that liver cancer can be managed as a chronic disease [3]. - Zhou Jian and Fang Jingyuan published a significant report in The Lancet, indicating that at least 60% of liver cancer cases are preventable by reducing risk factors such as viral hepatitis and alcohol consumption [3]. - A miRNA early diagnosis model for liver cancer developed by Zhou Jian and Fang Jingyuan has been successfully transformed into a clinical application, with over 5 million tests conducted, significantly improving early detection rates compared to traditional markers [3]. Group 3: Focus on Gastrointestinal Cancer - Fang Jingyuan has made significant contributions in the field of gastrointestinal cancer, particularly in early warning, diagnosis, prevention, and comprehensive treatment [4]. - Fang Jingyuan has innovatively analyzed gut microbiota to assess the effectiveness of postoperative chemotherapy and immunotherapy for colorectal cancer [4].